Invivoscribe Announces a Regional "Center of Excellence" Reference Laboratory in Beirut to Offer Specialized Gene Panels
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- Invivoscribe Technologies Inc., a global precision diagnostics company in oncology and personalized molecular medicine, announces a partnership with the American University of Beirut Medical Center (AUBMC) in Lebanon to create a new Center of Excellence. This facility will serve as an international service laboratory in the Middle East, testing for all hematologic diseases, including leukemia and lymphoma. This partnership will enable the American University of Beirut Medical Center to provide pharmaceutical and clinical partners in the Middle East the same high quality, reliable, standardized tests and bioinformatics tools provided by Invivoscribe's LabPMM clinical laboratories in the U.S.A., Japan and Germany. The establishment of this center also facilitates quicker turnaround times, which are important for clinical trial enrollment and tracking of patients during the course of treatment.
The Center of Excellence at the CAP-accredited Molecular Diagnostics Laboratory of the American University of Beirut Medical Center will expand the range of diagnostic services available in the Middle East, bringing a comprehensive array of new tests designed and manufactured in an ISO 13485 accredited facility. Most importantly, through this partnership, Invivoscribe's specialized next generation sequencing (NGS) gene panel tests including MyAML®, MyHeme®, and MyMRD® will become available in the Middle East. These tests identify and track primary driver mutations and their subclonal architectures, as well as the emergence of new driver mutations in patients with hematologic diseases. Other available tests include the comprehensive menu of IdentiClone® and LymphoTrack® Dx Assays for clonality, minimal residual disease (MRD) and somatic hypermutation testing. This Center of Excellence is the first of many that will facilitate international standardization of testing services, allowing medical centers around the world unprecedented access to Invivoscribe's proprietary assays and bioinformatics.
Invivoscribe Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, standardized reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics and personalized molecular medicine. Invivoscribe's PCR and NGS-based tests, reagents and bioinformatics tools are currently being used in more than 700 clinical and research laboratories in more than 160 countries. Invivoscribe currently has clinical laboratories located in North America, Europe and Asia, which provide international access to harmonized CLIA, CAP, and ISO 15189 accredited clinical testing and contract research organization (CRO) services. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies developing and commercializing companion diagnostics. As an international leader, Invivoscribe has long embraced the value of quality systems and develops all IVD products, including bioinformatics software, in compliance with ISO 13485 design controls, making them eligible to be submitted to worldwide regulatory authorities for registration.
For additional information please visit www.invivoscribe.com.
About the Department of Pathology and Laboratory Medicine at AUBMC
Currently, the Department of Pathology and Laboratory Medicine covers an area of 3,500 m2 and operates about 400 instruments distributed over 14 laboratory units and disciplines: Clinical Hematology, Clinical Chemistry, Clinical Microbiology, Biochemical Genetics, Flow Cytometry, Cytogenetics, Molecular Diagnostics, Surgical Pathology, Cytology, Immunohistochemistry, Neuromuscular, Blood Bank, Donor Management and Stem Cell Preparation. It offers a lab menu that exceeds 500 tests and covers all major Pathology and Laboratory Medicine specialties. Currently, more than 2,400,000 billable tests per year are performed by a team of highly skilled faculty and staff in the respective units of the lab and according to the best international standards of clinical laboratory testing. All faculty had their training in USA and the majority are diplomats of the American Board of Pathology. The Department is accredited by the College of American Pathologists (CAP) and meets the standards of the Joint Commission International (JCI).
About the American University of Beirut Medical Center (AUBMC)
Since 1902, AUBMC has been providing the highest standards of care to patients across Lebanon and the region. It is also the teaching hospital for the Faculty of Medicine at AUB (established in 1867), which has trained generations of medical students and physicians, and whose graduates are at leading institutions around the world. AUBMC is the only medical institution in the Middle East to have earned the five international accreditations of JCI, Magnet, CAP, ACGME-I and JACIE, thus attesting to its superior standards in patient-centered care, nursing, pathology/laboratory services and graduate medical education.
The Faculty of Medicine has graduated over 4,000 medical students and physicians; the Rafic Hariri School of Nursing provides excellent education for the nursing staff, and the Medical Center meets the healthcare needs of over 360,000 patient visits annually.
Kevin Dobyns 858-224-6600
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Invivoscribe, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Must Read Whitepaper, ‘Making Money With Network Slicing’, Hits The Shelves23.10.2018 10:00 | Pressemelding
Network Slicing Leader Cloudstreet Showcases the Vast Opportunities of this Promising New Mobile Business Model Espoo, Finland & Berlin, Germany, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cloudstreet, ‘The Network Slicing Company’, is pleased to announce the publication of its most recent industry whitepaper, “Making Money with Network Slicing”. A business-forward take on the practice, the paper puts slicing at the very center of the mobile industry’s transition now underway. With a focus on practical, market-ready models, the authors unravel the misconceptions about Network Slicing, exploring its potential to disrupt the cultural and business logjams that have hampered growth. Less about technology than a new way of doing business, Network Slicing has quickly risen from a mere buzzword to a budget line item, as mobile operators retool for the opportunities to come “Inherently disruptive, it will create new business ecosystems to support unique and evolving demands that touch quite literally e
Skybox Security Receives Common Criteria Certification23.10.2018 09:00 | Pressemelding
Receiving the internationally recognized certification will help organizations and particularly federal agencies assess the security and assurance of Skybox solutions SAN JOSE, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cybersecurity management, has received Common Criteria for Information Technology Security Evaluation (Common Criteria or CC) certification for Skybox Security Suite. Skybox is honored to receive the high-standard certification, demonstrating our commitment to top-tier products and delivering premium solutions to our customers. “The Common Criteria certification is an important milestone for the Skybox product,” said Skybox Security Vice President of R&D and CTO Ron Davidson. “It also enables us to provide cybersecurity solutions in the federal space, which not only requires the CC stamp of approval, but also has an acute need for the attack surface visibility and situational intelligence Skybox delivers.” The Skybox Security Suite en
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus23.10.2018 07:00 | Pressemelding
BRUSSELS, Belgium and CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Today UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) announced top-line results from a Phase 2b study evaluating the safety and efficacy of dapirolizumab pegol (DZP), an anti-CD40L pegylated Fab, in adults with moderately-to-severely active systemic lupus erythematosus (SLE) despite receiving standard-of-care treatment such as corticosteroids, anti-malarials and non-biological immunosuppressants. The primary endpoint of the study to demonstrate a dose response at 24 weeks on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) was not met (p=0.06). The study did demonstrate consistent and potentially meaningful improvements for the majority of clinical endpoints in patients treated with DZP compared with placebo. In addition, biomarker data demonstrated evidence of proof of biology. DZP was well tolerated and demonstrated an acceptable safety profile. Biogen and U
Constellation Brands Prices Offering of Senior Notes22.10.2018 23:52 | Pressemelding
VICTOR, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it priced the public offering of $2.15 billion aggregate principal amount of Senior Notes, consisting of (i) $650.0 million of Senior Floating Rate Notes due 2021 (the “senior floating rate notes”); (ii) $500.0 million of 4.400% Senior Notes due 2025 (the “2025 notes”) for a public offering price of 99.812% of the principal amount of the 2025 notes; (iii) $500.0 million of 4.650% Senior Notes due 2028 (the “2028 notes”) for a public offering price of 99.720% of the principal amount of the 2028 notes; and (iv) $500.0 million of 5.250% Senior Notes due 2048 (the “2048 notes”) for a public offering price of 99.592% of the principal amount of the 2048 notes (collectively, the “notes”). The notes will be senior obligations that rank equally with all of Constellation’s other senior unsecured indebtedness, and will be guaranteed by the subs
Forterra Announces Third Quarter 2018 Earnings Schedule22.10.2018 22:30 | Pressemelding
IRVING, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Forterra, Inc. (“Forterra”) (Nasdaq: FRTA) plans to release third quarter 2018 financial results before the market opens on Tuesday, November 6, 2018. A conference call to review financial results will also be held on Tuesday, November 6, 2018 at 10:00 a.m. Eastern time (9:00 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Charlie Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q3 2018 Forterra, Inc. Earnings Call Date: Tuesday, November 6, 2018 Time: 10:00 a.m. Eastern Time (9:00 a.m. Central) https://edge.media-server.com/m6/p/6dinjr8x Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Participant Passcode: 2467118 Replay Information A replay of the conference call will be available within 24 hours after the call on the “Events & Presentations” page under the Investor section of the Company’s website at
Ondot Announces Investment from Citi Ventures to Power Enriched Transactions22.10.2018 17:00 | Pressemelding
The investment will fuel Ondot’s international growth and give cardholders accessing info via Ondot’s platform increased control over and visibility into each transaction Santa Clara, Ca, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ondot Systems, the global leader in mobile payments services, today announced that it has secured a strategic funding investment from Citi Ventures. Ondot works directly with financial institutions to give consumers increased control over and visibility into their personal payment transactions. With Ondot, consumers can manage functions such as fraud alerts, transaction limits and purchase location restrictions, all from the convenience of an app on their smartphone or desktop. This investment will further support Ondot’s efforts to grow its international presence and product offerings. Today’s digitally connected consumers are looking for more ways to access detailed information about their digital lives — including personal payment transactions. Ondot’s platform add
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom